Upsher-Smith has 3 poster presentations at AES annual meeting
The presentations Upsher-Smith include data from its Phase 1 study of USL261, also known as midazolam nasal spray. The data from the trial characterizes the pharmacokinetics as well as the safety and tolerability in pediatric patients ranging in age from 2 to 13 who have epilepsy.
Upsher-Smith will also present its evaluation of Qudexy XR (topiramate) extended release capsules, which include effectiveness and safety profiles for the drug. Second-generation antiepileptic drugs will also be presented.
"Upsher-Smith is committed to developing treatment options and advancing care for patients living with challenging central nervous system diseases like seizure disorders," Upsher-Smith Chief Scientific Officer and Biotech Research Division President William Pullman said. "Since pediatric patients and their caregivers currently have few options for treating bouts of increased seizure activity, we are particularly pleased to be presenting Phase 1 results for USL261 that support its continued development in this important patient population."